Literature DB >> 20421272

Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.

Eva Giné1, Antoni Martinez, Neus Villamor, Armando López-Guillermo, Mireia Camos, Daniel Martinez, Jordi Esteve, Xavier Calvo, Ana Muntañola, Pau Abrisqueta, Maria Rozman, Ciril Rozman, Francesc Bosch, Elias Campo, Emili Montserrat.   

Abstract

BACKGROUND: The concept of "accelerated" chronic lymphocytic leukemia is frequently used by both pathologists and clinicians. However, neither histological criteria to define this form of chronic lymphocytic leukemia nor its clinical correlates and prognostic impact have been formally defined in large series of patients. DESIGN AND METHODS: Tissue biopsies from 100 patients with chronic lymphocytic leukemia were analyzed for the size of proliferation centers and their proliferation rate as assessed by mitosis count and Ki-67 immunostaining. Histological patterns were correlated with main clinico-biological features and outcome.
RESULTS: A suspicion of disease transformation was the main reason for carrying out tissue biopsy, which was performed at a median time of 14 months (range, 0 to 204 months) after the diagnosis of chronic lymphocytic leukemia. The biopsy showed histological transformation to diffuse large B-cell lymphoma in 22 cases. In the remaining 78 patients, the presence of expanded proliferation centers (broader than a 20x field) and high proliferation rate (either >2.4 mitoses/proliferation center or Ki-67 >40%/proliferation center) predicted a poor outcome and were selected to define a highly proliferative group. Thus, 23 patients with either expanded proliferation centers or high proliferation rate were considered as having "accelerated" chronic lymphocytic leukemia. These patients displayed particular features, including higher serum lactate dehydrogenase levels and more frequently elevated ZAP-70 than "non-accelerated" cases. The median survival from biopsy of patients with "non-accelerated" chronic lymphocytic leukemia, "accelerated" chronic lymphocytic leukemia and transformation to diffuse large B-cell leukemia was 76, 34, and 4.3 months, respectively (P<0.001).
CONCLUSIONS: The presence of expanded and/or highly active proliferation centers identifies a group of patients with "accelerated" chronic lymphocytic leukemia characterized by an aggressive clinical behavior.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20421272      PMCID: PMC2930954          DOI: 10.3324/haematol.2010.022277

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  29 in total

1.  B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes.

Authors:  Rajendra N Damle; Fabio Ghiotto; Angelo Valetto; Emilia Albesiano; Franco Fais; Xiao-Jie Yan; Cristina P Sison; Steven L Allen; Jonathan Kolitz; Philip Schulman; Vincent P Vinciguerra; Petra Budde; Jurgen Frey; Kanti R Rai; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

2.  Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.

Authors:  L Granziero; P Ghia; P Circosta; D Gottardi; G Strola; M Geuna; L Montagna; P Piccoli; M Chilosi; F Caligaris-Cappio
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

3.  Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

Authors:  R Peto; M C Pike
Journal:  Biometrics       Date:  1973-09       Impact factor: 2.571

4.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

5.  Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia.

Authors:  F Cobo; A Martínez; M Pinyol; L Hernández; M Gómez; S Beá; J Esteve; M Rozman; F Bosch; A López-Guillermo; E Montserrat; E Campo
Journal:  Leukemia       Date:  2002-06       Impact factor: 11.528

6.  Immunophenotype does not correlate with lymph node histology in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Sheryl L Asplund; Robert W McKenna; Michael S Howard; Steven H Kroft
Journal:  Am J Surg Pathol       Date:  2002-05       Impact factor: 6.394

7.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

Authors:  Marta Crespo; Francesc Bosch; Neus Villamor; Beatriz Bellosillo; Dolors Colomer; María Rozman; Silvia Marcé; Armando López-Guillermo; Elies Campo; Emili Montserrat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

8.  The lymph node in chronic lymphocytic leukemia.

Authors:  F R Dick; R D Maca
Journal:  Cancer       Date:  1978-01       Impact factor: 6.860

9.  Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome).

Authors:  Sílvia Beà; Armando López-Guillermo; Maria Ribas; Xavier Puig; Magda Pinyol; Ana Carrió; Lurdes Zamora; Francesc Soler; Francesc Bosch; Stephan Stilgenbauer; Dolors Colomer; Rosa Miró; Emili Montserrat; Elias Campo
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

10.  Lymphocytic lymphoma/B-chronic lymphocytic leukaemia--an immunohistopathological study of peripheral B lymphocyte neoplasia.

Authors:  S H Swerdlow; L J Murray; J A Habeshaw; A G Stansfeld
Journal:  Br J Cancer       Date:  1984-11       Impact factor: 7.640

View more
  47 in total

1.  Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Daniel Mertens; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

2.  LC-FACSeq is a method for detecting rare clones in leukemia.

Authors:  Eileen Y Hu; James S Blachly; Caner Saygin; Hatice G Ozer; Stephanie E Workman; Arletta Lozanski; Tzyy-Jye Doong; Chi-Ling Chiang; Seema Bhat; Kerry A Rogers; Jennifer A Woyach; Kevin R Coombes; Daniel Jones; Natarajan Muthusamy; Gerard Lozanski; John C Byrd
Journal:  JCI Insight       Date:  2020-06-18

3.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

4.  Haematological cancer: Richter's transformation in CLL-a distinct lymphoma.

Authors:  Preetesh Jain; Ken H Young
Journal:  Nat Rev Clin Oncol       Date:  2013-11-26       Impact factor: 66.675

Review 5.  The biology behind PI3K inhibition in chronic lymphocytic leukaemia.

Authors:  Valentín Ortiz-Maldonado; Marcial García-Morillo; Julio Delgado
Journal:  Ther Adv Hematol       Date:  2015-02

6.  Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.

Authors:  Mariam Hammadi; Pierre Youinou; Adrian Tempescul; Gabriel Tobón; Christian Berthou; Anne Bordron; Jacques-Olivier Pers
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

7.  Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.

Authors:  Lorenzo Falchi; Michael J Keating; Edith M Marom; Mylene T Truong; Ellen J Schlette; Rachel L Sargent; Long Trinh; Xuemei Wang; Susan C Smith; Nitin Jain; Zeev Estrov; Susan O'Brien; William G Wierda; Susan Lerner; Alessandra Ferrajoli
Journal:  Blood       Date:  2014-03-10       Impact factor: 22.113

8.  Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Michael J Conte; Deborah A Bowen; Gregory A Wiseman; Kari G Rabe; Susan L Slager; Susan M Schwager; Timothy G Call; David S Viswanatha; Clive S Zent
Journal:  Leuk Lymphoma       Date:  2014-02-17

9.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

10.  PET-positive lymphadenopathy in CLL-Not always Richter transformation.

Authors:  Naveen Pemmaraju; Preetesh Jain; L Jeffrey Medeiros; Jeffrey L Jorgenson; Nitin Jain; Jason Willis; Dimitrios P Kontoyiannis; Zeev Estrov; William G Wierda
Journal:  Am J Hematol       Date:  2017-02-07       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.